当前位置:首页>产品中心>单抗/多抗>Anti-Human CAMK2D Polyclonal Antibody|抗人CAMK2D多克隆抗体(靶标:人钙/钙调蛋白依赖性蛋白激酶IIδ)

Anti-Human CAMK2D Polyclonal Antibody|抗人CAMK2D多克隆抗体(靶标:人钙/钙调蛋白依赖性蛋白激酶IIδ)

  • 货号:RB9THC230014
  • 价格:面议
  • 点击:733
   一键复制产品信息 复制成功!

产品介绍

产品参数

形态Liquid
宿主种属Rabbit
克隆性Polyclonal
抗体亚型IgG
纯化方式Purified by antigen affinity column.
内毒素水平Please contact with the lab for this information.
应用ELISA, IHC, WB
种属反应性Mouse, Human, Rat
靶标CAMK2D, CAMKD, CaM kinase II subunit delta, CaMK-II subunit delta, Calcium/calmodulin-dependent protein kinase type II subunit delta, EC:2.7.11.17
免疫原E. coli - derived recombinant Human CAMK2D (Thr8-Asn313).
储存缓冲液0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
产品使用说明ELISA:1:5000-1:20000;IHC:1:50-1:500;WB:1:500-1:2000
登录号Q13557
背景信息

Calcium/calmodulin-dependent protein kinase type II subunit delta (CAMK2D) is a ~56 kDa protein. Calcium/calmodulin-dependent protein kinase involved in the regulation of Ca(2+) homeostatis and excitation-contraction coupling (ECC) in heart by targeting ion channels, transporters and accessory proteins involved in Ca(2+) influx into the myocyte, Ca(2+) release from the sarcoplasmic reticulum (SR), SR Ca(2+) uptake and Na(+) and K(+) channel transport. Targets also transcription factors and signaling molecules to regulate heart function. In its activated form, is involved in the pathogenesis of dilated cardiomyopathy and heart failure. Contributes to cardiac decompensation and heart failure by regulating SR Ca(2+) release via direct phosphorylation of RYR2 Ca(2+) channel on 'Ser-2808'. In the nucleus, phosphorylates the MEF2 repressor HDAC4, promoting its nuclear export and binding to 14-3-3 protein, and expression of MEF2 and genes involved in the hypertrophic program.

1. Little, GH. et al. (2007) The Journal of biological chemistry 282, 7219-31. PMID: 17179159
2. Rose, AJ. et al. (2006) The Journal of physiology 574, 889-903. PMID: 16690701
备注For research use only
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Certolizumab Neutralizing Recombinant Antibody |抗赛妥珠单抗中和重组抗体(靶标:赛妥珠单抗中和抗体) 1322
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 1053
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 1036
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 1238
Anti-Sintilimab Neutralizing Recombinant Antibody |抗信迪利单抗中和重组抗体(靶标:信迪利单抗中和抗体) 1173
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 1204
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 1102
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 1101
Anti-Toripalimab Neutralizing Recombinant Antibody |抗特瑞普利单抗中和重组抗体(靶标:特瑞普利单抗中和抗体) 953
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 1319
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 1364
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 1312
Anti-Tiragolumab Neutralizing Recombinant Antibody |抗替拉戈单抗中和重组抗体(靶标:替拉戈单抗中和抗体) 1200
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 954
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 1150
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 1346
Anti-Ibalizumab Neutralizing Recombinant Antibody |抗伊巴利珠单抗中和重组抗体(靶标:伊巴利珠单抗中和抗体) 1450
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 1404
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 1321
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 1337
总计 33036 个记录,共 1652 页,当前第 1651 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周日 9:00-22:30